Is your drug covered by Medicare Part D?
Of 2,259 drugs, 1,009 are on at least 90% of 2026 Part D formularies. Each drug's page shows the share of plans that list it, its usual tier and how often prior authorization applies. Part D spending was highest for Eliquis in 2024: $20.8 billion, what plans and patients paid at the pharmacy before rebates (CMS Part D Spending by Drug).
Which drugs cost Medicare the most?
| Drug | Plans covering | Usual tier | Prior authorization | Spending 2024 |
|---|---|---|---|---|
| Eliquis (apixaban) | 100% | Tier 3 | 0% | $20.8 billion |
| Ozempic (semaglutide) | 99% | Tier 3 | 99.4% | $13.0 billion |
| Jardiance (empagliflozin) | 100% | Tier 3 | 0% | $11.4 billion |
| Mounjaro (tirzepatide) | 97% | Tier 3 | 99.4% | $6.3 billion |
| Xarelto (rivaroxaban) | 100% | Tier 3 | 0% | $6.2 billion |
| Humira (adalimumab) | 54% | Tier 5 | 100% | $5.6 billion |
| Trulicity (dulaglutide) | 95.4% | Tier 3 | 99.4% | $5.5 billion |
| Trelegy (fluticasone furoate / umeclidinium / vilanterol) | 100% | Tier 3 | 0% | $5.3 billion |
| Farxiga (dapagliflozin) | 100% | Tier 3 | 0% | $5.3 billion |
| Revlimid (lenalidomide) | 3.5% | Tier 5 | 100% | $4.2 billion |
| Entresto (sacubitril / valsartan) | 100% | Tier 3 | 0.9% | $4.0 billion |
| Januvia (sitagliptin phosphate) | 100% | Tier 3 | 0.3% | $3.8 billion |
| Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | 100% | Tier 5 | 0% | $3.5 billion |
| Xtandi (enzalutamide) | 100% | Tier 5 | 99.4% | $3.4 billion |
| Stelara (ustekinumab) | 72.7% | Tier 5 | 99% | $3.4 billion |
| Enbrel (etanercept) | 100% | Tier 5 | 98.5% | $3.0 billion |
| Vyndamax (tafamidis) | 32.1% | Tier 5 | 98.5% | $2.8 billion |
| Lenalidomide | 100% | Tier 5 | 98.8% | $2.6 billion |
| Dupixent (dupilumab) | 100% | Tier 5 | 100% | $2.5 billion |
| Myrbetriq (mirabegron) | 79.9% | Tier 3 | 0% | $2.3 billion |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.